A study of the use of robotic surgery for outpatient surgery to determine the effect on recovery
| ISRCTN | ISRCTN18159384 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN18159384 |
| ClinicalTrials.gov (NCT) | Nil known |
| Clinical Trials Information System (CTIS) | Nil known |
| Integrated Research Application System (IRAS) | 327536 |
| Protocol serial number | CPMS 56913, IRAS 327536 |
| Sponsor | Portsmouth Hospitals NHS Trust |
| Funder | Intuitive Surgical Limited |
- Submission date
- 26/07/2023
- Registration date
- 11/09/2023
- Last edited
- 19/07/2024
- Recruitment status
- Recruiting
- Overall study status
- Ongoing
- Condition category
- Surgery
Plain English summary of protocol
Background and study aims
This study is part of a research project to investigate the role of a robotic outpatient surgery program in the NHS. Outpatient surgery means that the patient is able to go home within 24 hours after the surgery, usually without the need to stay in hospital overnight. Robotic surgery means that the operation is done by a human surgeon using an advanced tool (the robotic platform) to perform the surgery through small cuts in the body. This robot is not autonomous, meaning that at no point is a robot performing the operation itself, a human surgeon will be controlling the robot during the entire operation.
Who can participate?
Patients aged 18 years or above within Portsmouth Queen Alexandra Hospital who are scheduled for a robotic procedure.
What does the study involve?
The researchers want to study clinical outcomes, such as how quickly participants are able to leave the hospital after surgery, economic outcomes, such as how much robotic outpatient surgery costs to the NHS, and efficiency outcomes, such as whether patients are able to be operated on sooner.
What are the possible benefits and risks of participating?
Robotic surgery has been around since the early 2000s and is already being used successfully for these types of operations across the world. However, the benefits and costs of robotic surgery have not yet been fully examined. That is why this study has been set up to find out the impact that the robotic platform has on outpatient surgery within the NHS.
Where is the study run from?
Portsmouth Hospitals NHS Trust (UK)
When is the study starting and how long is it expected to run for?
July 2023 to September 2026
Who is funding the study?
Intuitive Surgical Limited (UK)
Who is the main contact?
1. Ian Gedge, ian.gedge@porthosp.nhs.uk
2. Prof. Jim Khan, jim.khan@porthosp.nhs.uk
Contact information
Public
1st Floor Lancaster House
Queen Alexandra Hospital
Portsmouth
PO6 3LY
United Kingdom
| Phone | +44 (0)2392286000 |
|---|---|
| ian.gedge@porthosp.nhs.uk |
Scientific
Queen Alexandra Hospital
Cosham
PO6 3LY
United Kingdom
| 0000-0002-3031-4495 | |
| Phone | +44 (0)23292 286000 |
| jim.khan@porthosp.nhs.uk |
Study information
| Primary study design | Observational |
|---|---|
| Study design | Observational cohort study |
| Secondary study design | Cohort study |
| Participant information sheet | 44006_PIS_V1.1_01Jul23.pdf |
| Scientific title | Multispecialty robotic outpatient surgery program for improved length of stay and recovery |
| Study acronym | MAYFLY |
| Study objectives | A multispecialty robotic outpatient surgery program will improve length of stay and recovery time for patients in a national healthcare setting. |
| Ethics approval(s) | Approved 06/07/2023, West of Scotland REC 5 (West of Scotland Research Ethics Service, Ground Floor Ward 11, Dykebar Hospital, Grahamston Road, Paisley, PA2 7DE, UK; +44 (0)141 314 0213; WoSREC5@ggc.scot.nhs.uk), ref: 23/WS/0100 |
| Health condition(s) or problem(s) studied | Surgery |
| Intervention | A prospective, single-centre, observational study assessing the implementation of a multispecialty robotic outpatient program in the national healthcare setting. The study is looking to recruit all patients treated in the robotic outpatient unit, which we estimate will lead to 600-1200 inclusions per year. The researchers will not be seeking to randomise these patients. Participation in the trial will not alter surgical care or treatment in any way, shape, or form. There is no direct benefit and no additional risk for patients participating in this research. Eligible robotic outpatients will be recruited. A patient is eligible when he/she meets all the inclusion criteria and none of the exclusion criteria of this study. All eligible patients will be logged in a screening log to ensure no patient selection will occur. After the identification of possible eligible participants, the patient is correctly informed about the trial and after an acceptable period of consideration, voluntary informed consent will be asked. If a person is willing to participate, the informed consent form will be signed. Only subjects who have signed the study's informed consent will be included in the study. The participants have the right to withdraw at any time without reason or penalty. The total study duration will be approximately 3 years. Study follow-up will be 12 months after the date of surgery. Patients will be asked to fill in Quality of Life and Quality of Recovery questionnaires before surgery, and at 2, 7, 30, and 365 days after surgery. The Baseline visit After informed consent is obtained, pre-operative baseline information will be collected. At this moment in time the participant will be asked to complete the aforementioned questionnaires. Patients have a standard of care preoperative clinical visit, and information will be collected from the medical records. The Operative Procedure visit During the operation routinely recorded parameters will be collected. These include how long the operation takes, system and instrument use, conversion to an open surgery, and any complications during the surgery. The Post-Operative Course Following surgery, patients will be taken to the postoperative recovery unit as per standard clinical care. Patients will receive standard post-operative care as per clinical pathways, with all treatment decisions made as per clinician expertise. Follow-up visits 2 days (-12 to +24 hours) At 2 days postoperatively, the patient will receive two questionnaire surveys to fill out (digitally or by mail). 7 days (-1 to +3 days) At 7 days postoperatively, the patient will receive one questionnaire surveys to fill out (digitally or by mail). Patient records will be checked to identify any readmissions, reinterventions, and SAEs. 30 days (+- 7 days) At 30 days postoperatively, the patient will receive two questionnaire surveys to fill out (digitally or by mail). The patient will be contacted for a telephone follow-up call, which is estimated to take around 5 minutes. A member of the research team will collect postoperative follow-up data from the patients' medical notes. 90 days (+/- 14 days) A member of the research team will collect postoperative follow-up data from the patients' medical notes. 365 days (+/- 14 days) At 365 days postoperatively, the patient will receive one questionnaire survey to fill out (digitally or by mail), after which the End of Study form will be completed. The trial requires one additional follow-up phone call at 30 days and does not require any other additional investigations or patient contact throughout its duration. |
| Intervention type | Procedure/Surgery |
| Primary outcome measure(s) |
1. Quality of life measured using EQ-5D and QoR-15 questionnaires at baseline and postoperative |
| Key secondary outcome measure(s) |
1. Need for and benefits of additional endoscope sterilizing capacity throughout the robotic outpatient surgery program measured by comparing the amount of endoscopes sterilized with the maximum capacity of the sterilizing unit (defined as fraction of maximum potential) in the first, second, and third year of the program |
| Completion date | 30/09/2026 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 2000 |
| Key inclusion criteria | 1. All patients treated at Portsmouth Hospitals University NHS Trust who undergo either a robotic outpatient procedure (defined as an anticipated post-procedure discharge time less than 24 hours) or a planned elective surgical inpatient procedure that is anticipated to be discharged within 24 hours. 2. Patients aged 18 years or above. 3. Must be willing and able to comply with study requirements. 4. Must indicate their understanding of the study and willingness to participate by signing an appropriate informed consent form. |
| Key exclusion criteria | 1. Patients that have multiple resections planned in the same procedure. 2. Mental incapacity to understand or consent to study procedures. 3. Anticipated difficulty for patient to comply with protocol requirements. 4. Unable to comply with the follow up schedule. 5. Patients participating in additional research studies, which may impact the outcomes of this study. 6. Pregnant or breastfeeding patients. |
| Date of first enrolment | 01/09/2023 |
| Date of final enrolment | 30/06/2026 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
Cosham
Portsmouth
PO6 3LY
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| IPD sharing plan | The data-sharing plans for the current study are unknown and will be made available at a later date |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | version 1.1 | 01/07/2023 | 04/08/2023 | No | Yes |
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Additional files
- 44006_PIS_V1.1_01Jul23.pdf
- Participant information sheet
Editorial Notes
19/07/2024: The following changes were made:
1. The recruitment end date was changed from 01/07/2024 to 30/06/2026.
2. The overall study end date was changed from 01/07/2025 to 30/09/2026.
02/10/2023: Internal review.
26/07/2023: Trial's existence confirmed by the National Institute for Health and Care Research (NIHR) (UK).